Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

Research output: Contribution to journal › Article › Academic › peer-review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{38b3e1e9e8dd43d0af2ea3ca6c05d3a8,

title = "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer",

author = "F. Caponigro and J.H.M. Schellens and P. Fumoleau",

year = "2001",

language = "Undefined/Unknown",

volume = "38",

pages = "70--74",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}